The Effects of Prebiotics on Cognitive Functioning and Weight Gain in Psychosis
NCT03153046 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39
Last updated 2019-04-18
Summary
The investigators propose a maltodextrin-controlled cross over experimental medicine study that aims to examine the role of the immune system in cognitive processes and weight gain in 40 adult patients with psychosis, stable on antipsychotic medication for over 1 month. There is evidence suggesting the immune system is linked to brain function and weight gain, both parameters that has been implicated in psychosis and antipsychotic use, and may underlie some schizophrenic features. The fermentation of galacto-oligosaccharides (GOS), which are short chain carbohydrates composed mostly of galactose sugar molecules, by the intestinal microbiota has been shown to modulate the immune system and reduce the inflammatory response in both animals and humans. Since the intestinal ecosystem is highly sensitive to dietary changes, the growth of beneficial gut bacteria can be enhanced using a natural food supplement similar to GOS known as prebiotics. The study will be controlled by taking maltodextrin as a control supplement. Both prebiotics and maltodextrin are short chain sugar compounds. The study will involve asking patients to take dietary supplement for a total of 24 weeks; GOS for 12 weeks and maltodextrin for 12 weeks as a control. Participants will be randomised into groups, with half receiving maltodextrin followed by GOS, and half receiving GOS followed by maltodextrin. Participants will be assessed on cognitive function and weight gain at 3 specified time points.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
prebiotics
Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
- DIETARY_SUPPLEMENT
-
Maltodextrin
Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
Sponsors & Collaborators
-
Clasado Biosciences Ltd
collaborator INDUSTRY -
University of Oxford
lead OTHER
Principal Investigators
-
Belinda Lennox, MD · University of Oxford
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-05-08
- Primary Completion
- 2018-09-30
- Completion
- 2018-12-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
NCT01242371 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Dietary Supplements in Schizophrenia
NCT01786239 ·Status: COMPLETED ·Phase: NA
-
Effect of Dietary Fiber Supplement on the Intestinal Microbiota Among Schizophrenia Patients
NCT03552237 ·Status: UNKNOWN ·Phase: NA
-
Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia
NCT02210962 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
NCT00567203 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
NCT03883360 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
NCT00728728 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
NCT04411225 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
NCT04518319 ·Status: SUSPENDED ·Phase: PHASE2
-
Biological Evaluation of Dietary Supplement Liposomal Glutathione
NCT01967667 ·Status: COMPLETED ·Phase: NA
-
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
NCT01222793 ·Status: COMPLETED
-
Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive
NCT01927276 ·Status: COMPLETED ·Phase: NA
-
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Gluten Free Diet in People With Schizophrenia: A Pilot Study
NCT01558557 ·Status: COMPLETED ·Phase: NA
-
Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or
NCT02167724 ·Status: COMPLETED ·Phase: NA
-
The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia
NCT06789471 ·Status: COMPLETED ·Phase: NA
-
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
NCT03809325 ·Status: COMPLETED
-
A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis
NCT02398292 ·Status: COMPLETED ·Phase: NA
-
Ketogenic Diet in People With Schizophrenia
NCT05968638 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
NCT00401089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
NCT00396643 ·Status: COMPLETED ·Phase: PHASE4
-
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
NCT01269710 ·Status: COMPLETED
-
Neuroinflammation Markers in Subjects With Psychotic Symptoms
NCT05815225 ·Status: UNKNOWN
-
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
NCT00585390 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2